Actively Recruiting

Phase Not Applicable
Age: 22Years - 88Years
All Genders
NCT05712824

V-Lap System For Wirelessly Measuring And Monitoring Left Atrial Pressure (LAP) In Patients With Advance CHF

Led by Vectorious Medical Technologies Ltd. · Updated on 2025-05-30

10

Participants Needed

3

Research Sites

310 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The objective of this study is to evaluate the safety and performance of the V-LAP System in subjects with New York Heart Association (NYHA) functional class II and III HF, irrespective of left ventricular ejection fraction.

CONDITIONS

Official Title

V-Lap System For Wirelessly Measuring And Monitoring Left Atrial Pressure (LAP) In Patients With Advance CHF

Who Can Participate

Age: 22Years - 88Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of ischemic or non-ischemic cardiomyopathy with heart failure for at least 6 months
  • NYHA Class II or III heart failure documented at baseline visit
  • At least one heart failure hospitalization or equivalent visit requiring IV diuretic in the past 12 months (if CRT device implanted, hospitalization must be at least 30 days after implantation)
  • Elevated outpatient BNP (≥300 pg/ml) or NT-proBNP (≥1,500 pg/ml) within 90 days before baseline visit, adjusted for BMI and ARNI use
  • Receiving maximally-tolerated guideline-directed medical therapy for heart failure as per ACC/AHA or ESC guidelines
  • Stable drug doses for at least 1 month prior to baseline visit (except diuretics)
  • Cardiac rhythm management device therapy implanted at least 3 months before baseline visit if indicated
  • Provide informed consent and able to comply with study procedures
Not Eligible

You will not qualify if you...

  • Age under 22 or over 88 years
  • NYHA class IV and ACC/AHA stage D heart failure
  • Major cardiovascular or neurovascular events within 6 months before baseline
  • Resting systolic blood pressure below 90 or above 180 mmHg
  • Left ventricular end-diastolic diameter over 8 cm
  • Atrial septal defect or patent foramen ovale with significant shunting or prior atrial septal interventions
  • Untreated severe valve lesions or significant cardiac conditions causing heart failure
  • Uncontrolled abnormal heart rhythms (tachycardia or bradycardia below 45 bpm)
  • Intractable heart failure with resting symptoms despite maximal therapy
  • Intolerance to ACE inhibitors, ARBs, ARNIs, or beta-blockers for patients with reduced ejection fraction
  • Recent acute coronary events, major surgeries, or cardiac device procedures within 90 days
  • Ineligibility for emergency open-heart, thoracic, or vascular surgery
  • Women of childbearing age
  • Life expectancy under 12 months or listed/received cardiac transplant
  • Coagulopathy or contraindications to antiplatelet/anticoagulant treatments
  • Severe allergies to contrast dye
  • Severe kidney or liver impairment
  • Recent gastrointestinal bleeding
  • Severe chronic lung disease requiring oxygen or steroids
  • Active infection requiring antibiotics or elevated white blood count
  • History of active drug addiction, alcohol abuse, or recent psychiatric hospitalization
  • Current participation in another clinical study
  • Contraindications for trans-septal puncture or related imaging procedures
  • Anatomical or vascular access issues preventing implantation
  • Severe pulmonary hypertension not responsive to vasodilators
  • Resting systolic blood pressure not correctable with fluids or vasodilators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Aleksandre Aladashvili Clinic

Tbilisi, Georgia, Georgia

Actively Recruiting

2

Jerarsi Clinic

Tbilisi, Georgia, Georgia

Actively Recruiting

3

Tbilisi Medical Institute- TIM

Tbilisi, Georgia, Georgia

Actively Recruiting

Loading map...

Research Team

D

Dedi Erdheim

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

V-Lap System For Wirelessly Measuring And Monitoring Left Atrial Pressure (LAP) In Patients With Advance CHF | DecenTrialz